"description","uuid:ID","label","id","studyDesignRationale","name"
"The main design for the study","da18b443-c218-41b2-89a2-16307c0a06de","","StudyDesign_1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","Study Design 1"
